Country/Region: Israel
Submission Guidelines

Guidelines for the Submission of a Request to Include a Pharmaceutical Product in the National List of Health Services - Appendix D: Instructions for Performing an Economic Assessment (2010)
PDF in English (page 14-21)

Submission Guidelines Source:

State of Israel Ministry of Health – Pharmaceutical Administration
http://www.health.gov.il/english/

Additional Information:

Guidelines for the Submission of a Request to Include a Pharmaceutical Product in the National List of Health Services – Appendix B: Instructions for Performing an Economic Assessment (2002)
PDF in English (page 24-28)

Last Webpage Update: Wednesday, April 20, 2011

Submission Guidelines Key Features:

Key Features:  
Title and year of the document
Guidelines for the Submission of a Request to Include a Pharmaceutical Product in the National List of Health Services - Appendix D: Instructions for Performing an Economic Assessment (2010) 
Affiliation of authors
Pharmacoepidemiology and Pharmacoeconomics Department, Pharmaceutical Administration of the Ministry of Health 
Purpose of the document
Submission for a listing of new drug products 
Standard reporting format included
Yes 
Disclosure
Not stated 
Target audience of funding/ author's interests
Pharmaceutical companies, Pharmacoepidemiology and Pharmacoeconomics Department, Pharmaceutical Administration of the Ministry of Health 
Perspective
Sick Funds of the National Health Insurance 
Indication
Yes 
Target population
Yes 
Subgroup analysis
Not stated 
Choice of comparator
Not specific, all alternatives 
Time horizon
Not stated 
Assumptions required
Not stated 
Preferred analytical technique
Cost effectiveness evaluation 
Costs to be included
Treatment costs, resources to support therapy and treat side effects and treatment failures 
Source of costs
Ministry of Health’s ambulatory services’ price 
Modeling
Yes, requires details 
Systematic review of evidences
Yes 
Preference for effectiveness over efficacy
Not stated 
Preferred outcome measure
Final outcomes 
Preferred method to derive utility
Not stated 
Equity issues stated
Not stated 
Discounting costs
Not stated 
Discounting outcomes
Not stated 
Sensitivity analysis-parameters and range
Impact of the uncertainty of the different data on the strength of the assessments. 
Sensitivity analysis-methods
Not stated 
Presenting results
Not stated 
Incremental analysis
Not stated 
Total costs vs effectiveness (cost/effectiveness ratio)
Not stated 
Portability of results (Generalizability)
Yes 
Financial impact analysis
Yes, first three years following the inclusion. 
Mandatory or recommended or voluntary
 

Country Selection Page | PE Guidelines Index Page